Bill T. Ameredes, PhD, William J. Calhoun, MD

Slides:

Advertisements

Similar presentations

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Advertisements

Maria B. Sukkar, PhD, Shaoping Xie, PhD, Nadia M

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

Asthmatic airway epithelial cells differentially regulate fibroblast expression of extracellular matrix components Stephen R. Reeves, MD, PhD, Tessa.

What drives prescription patterns in pediatric asthma management?

Allergen immunotherapy: A practice parameter third update

Anne M. Fitzpatrick, PhD, MSCR, W. Gerald Teague, MD

Alexandra Kazaks, MA, RD, Janet Y. Uriu-Adams, PhD, Judith S

Fatty acids, inflammation, and asthma

Obstructive sleep apnea syndrome and inflammation

Mechanism of glucocorticoid protection of airway smooth muscle from proasthmatic effects of long-acting β2-adrenoceptor agonist exposure Gustavo Nino,

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Ann-Marie M. Schoos, MD, PhD, Jacob D

Prostaglandin E2 inhibits mast cell–dependent bronchoconstriction in human small airways through the E prostanoid subtype 2 receptor Jesper Säfholm,

Prostaglandin E2 suppresses CCL27 production through EP2 and EP3 receptors in human keratinocytes Naoko Kanda, MD, PhD, Hiroshi Mitsui, MD, PhD, Shinichi.

David A. Khan, MD Journal of Allergy and Clinical Immunology

Is 9 more than 2 also in allergic airway inflammation?

Desensitization to Chemotherapeutic Agents

Intramuscular Versus Intravenous Immunoglobulin Replacement Therapy and Measurement of Immunoglobulin Levels During Immunoglobulin Replacement Therapy

Fatty acids, inflammation, and asthma

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Corticosteroid insensitivity of chemokine expression in airway smooth muscle of patients with severe asthma Po-Jui Chang, MD, Pankaj K. Bhavsar, PhD,

Physician needs in health informatics: Just ask the docs

William J. Calhoun, MD, Tmirah Haselkorn, PhD, Dave P

Jewlya Lynn, PhD, Sophie Oppenheimer, MS, MPH, Lorena Zimmer, MA

Superior anti-inflammatory effects of narrow-spectrum kinase inhibitors in airway smooth muscle cells from subjects with chronic obstructive pulmonary.

β-Agonist enhances type 2 T-cell survival and accumulation

Reply Journal of Allergy and Clinical Immunology

Jon Genuneit, MD, MSc Journal of Allergy and Clinical Immunology

Phillip Lieberman, MD, Michael Tankersley, MD

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Staphylococcus aureus colonization is associated with wheeze and asthma among US children and young adults Meghan F. Davis, PhD, Roger D. Peng, PhD,

What are the best outcome measurements for atopic eczema

Sheena D. Brown, PhD, MSCR, Katherine M. Baxter, BS, Susan T

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Biosimilars and drug development in allergic and immunologic diseases

CC chemokine receptors CCR1 and CCR4 are expressed on airway mast cells in allergic asthma Kawa Amin, PhD, Christer Janson, MD, PhD, Ilkka Harvima, MD,

What is an “eosinophilic phenotype” of asthma?

Increased sputum endotoxin levels are associated with an impaired lung function response to oral steroids in asthmatic patients Charles McSharry, PhD,

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Personalized asthma therapy in blacks—the role of genetic ancestry

Autophagy: Nobel Prize 2016 and allergy and asthma research

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Matthew J. Loza, PhD, Susan Foster, PhD, Stephen P

Alexandra Kazaks, MA, RD, Janet Y. Uriu-Adams, PhD, Judith S

Syk expression and IgE-mediated histamine release in basophils as biomarkers for predicting the clinical efficacy of omalizumab Donald W. MacGlashan,

Prevention of food allergy: Beyond peanut

The National Institutes of Allergy and Infectious Diseases networks on asthma in inner- city children: An approach to improved care William W. Busse,

CCL17/thymus and activation-regulated chemokine induces calcitonin gene–related peptide in human airway epithelial cells through CCR4 Kandace Bonner,

The Editors' Choice Journal of Allergy and Clinical Immunology

Clinical safety of Food Allergy Herbal Formula-2 (FAHF-2) and inhibitory effect on basophils from patients with food allergy: Extended phase I study

Measles and immunomodulation

The Editors' Choice Journal of Allergy and Clinical Immunology

Steroids completely reverse albuterol-induced β2-adrenergic receptor tolerance in human small airways Philip R. Cooper, PhD, Reynold A. Panettieri, MD

Päivi M. Salo, PhD, Samuel J. Arbes, DDS, MPH, PhD, Patrick W

Macrolide antibiotics and asthma treatment

Asthma: The past, future, environment, and costs

Environmental factors and eosinophilic esophagitis

Valérie Bougault, PhD, Julie Turmel, MSc, Louis-Philippe Boulet, MD

The GILL study: Glycerin-induced local reactions in immunotherapy

Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma Oliver Noga, MD, Gerald Hanf, MD,

The use of serum-specific IgE measurements for the diagnosis of peanut, tree nut, and seed allergy Jennifer M. Maloney, MD, Magnus Rudengren, BSc, Staffan.

Safety and efficacy of repeated monthly carboplatin desensitization

Transforming growth factor β1 increases fibronectin deposition through integrin receptor α5β1 on human airway smooth muscle Lyn M. Moir, PhD, Janette.

Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease Jaclyn Smith, MD, PhD, Emily Owen, MPhil, John Earis, MD,

Natural history of cow’s milk allergy

Differences in airway remodeling between subjects with severe and moderate asthma Carmela Pepe, MD, Susan Foley, MD, Joanne Shannon, MD, Catherine Lemiere,

Primary prevention of asthma and allergy

CCL17/thymus and activation-regulated chemokine induces calcitonin gene–related peptide in human airway epithelial cells through CCR4 Kandace Bonner,

Presentation transcript:

Modulation of GM-CSF release by enantiomers of β-agonists in human airway smooth muscle Bill T. Ameredes, PhD, William J. Calhoun, MD Journal of Allergy and Clinical Immunology Volume 116, Issue 1, Pages 65-72 (July 2005) DOI: 10.1016/j.jaci.2005.03.007 Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 1 GM-CSF release with enantiomers and propranolol (10 μmol/L; hatched bars) relative to control (dashed line; [enantiomer]=0). (R)-albuterol (n=6), (S)-albuterol (n=4), (R)-+(S)-albuterol (n=4), (R,R)-formoterol (n=6), (S,S)-formoterol (n=4), or (R,R)-+(S,S)-formoterol (n=4). Symbols indicate P < .05 for comparison versus ∗respective control, +respective enantiomer at same concentration, ∧respective (R)-enantiomer at same concentration, and #(R)-albuterol at same concentration. Journal of Allergy and Clinical Immunology 2005 116, 65-72DOI: (10.1016/j.jaci.2005.03.007) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 2 A, GM-CSF release by HASMC with propranolol (○) and ICI-118,511 (•). ∗P < .05 compared with control (0 μmol/L propranolol=467 pg/mL ± 4 pg/mL; 0 μmol/L ICI-118,551=1079 pg/mL ± 28 pg/mL); n=5 experiments per concentration. B, Intracellular cAMP levels in HASMC with propranolol (n=2) and ICI-118,551 (n=4); significance as in A; mean baseline cAMP=1.9 pmol/mL ± 0.1 pmol/mL. Journal of Allergy and Clinical Immunology 2005 116, 65-72DOI: (10.1016/j.jaci.2005.03.007) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 3 Propranolol concentration and GM-CSF release response relationship versus single concentration (10 μmol/L) of either (R)-albuterol (left) or (R,R)-formoterol (right) in HASMC. Symbols indicate P < .05 for comparison versus∗ respective control (0 μmol/L propranolol), ∧(R)-albuterol at same concentration; n=5 experiments/bar. Journal of Allergy and Clinical Immunology 2005 116, 65-72DOI: (10.1016/j.jaci.2005.03.007) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 4 Intracellular cAMP with increasing (R)-albuterol alone (□; n=2) and with increasing (R)-albuterol plus propranolol (•; 0 μmol/L or 10 μmol/L; n=2), expressed as a function of baseline intracellular cAMP in HASMC with no drugs added (horizontal dashed line; 1.2 pmol/mL ± 0.4 pmol/mL). Journal of Allergy and Clinical Immunology 2005 116, 65-72DOI: (10.1016/j.jaci.2005.03.007) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 5 GM-CSF release with dibutyryl cAMP alone (•) and with dibutyryl cAMP plus propranolol (○; 100 μmol/L),∗P < .05; versus 0 μmol/L dibutyryl cAMP, †P < .05; versus dibutyryl cAMP alone at same concentration; r2>.99 for regression of both data sets; horizontal dashed line indicates control GM-CSF release with 0 μmol/L dibutyryl cAMP (1672 pg/mL ± 22 pg/mL); n=5 experiments per set. Journal of Allergy and Clinical Immunology 2005 116, 65-72DOI: (10.1016/j.jaci.2005.03.007) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 6 Effects of dexamethasone (Dex) in combination with enantiomers. GM-CSF expressed as ratios relative to –Dex, 0 enantiomer control (range: 1800-2700 pg/mL); percentage change values as shown. ∗P < .05 vs –Dex, 0 agonist (no drugs) control; +P < .05 vs –Dex, 10 μmol/L agonist; ∧P < .05 vs +Dex, 0 agonist; n=4-10 experiments/bar. Journal of Allergy and Clinical Immunology 2005 116, 65-72DOI: (10.1016/j.jaci.2005.03.007) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions